The FDA has approved Moderna's mRNA-based flu vaccine, the first such product cleared by the agency. The vaccine is intended for older Americans. Approval followed review of trial data submitted by the manufacturer.
Approval advances protection for older Americans through regulatory oversight and public investment in mRNA technology.
“Value of government action to prioritize vulnerable populations”
Clearance after review is noted, yet skepticism remains warranted regarding real-world performance and past platform claims.
“Institutional caution and individual choice over mandates”
Private development cleared a regulatory gate; approval itself imposes no usage obligation.
“Bodily autonomy and limits on centralized approval power”
All views accept framing of arduous review and senior targeting without examining trial comparisons or commercial incentives.
“Missing data on relative efficacy and platform path dependence”